Theodore Nyquist, MD
Family Medicine · McMinnville, ORNPI 1609972926
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,341 and has fallen 58.4% since, to $558 in 2025. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$567
- AstraZeneca$558
- Novo Nordisk$545
- Lilly USA, LLC$474
- Pfizer$413
- GSK$279
- plus $3K from 38 others
What the payments were for
- Food & beverage$5,27398%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,359 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $31,625 |
| OzempicSemaglutide | 19 | $26,182 |
| XareltoRivaroxaban | 33 | $23,651 |
| JardianceEmpagliflozin | 26 | $17,315 |
| MounjaroTirzepatide | 16 | $15,488 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,952 |
| Xtampza ErOxycodone Myristate | 12 | $11,666 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,001 |
| JanuviaSitagliptin Phosphate | 13 | $9,570 |
| Humalog Kwikpen U-100Insulin Lispro | 25 | $8,881 |
| KerendiaFinerenone | 12 | $7,913 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $7,165 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $6,980 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,732 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 147 | $5,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $413 | $33,05452 claims |
| Novo NordiskOzempic | $545 | $26,18219 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $279 | $24,55946 claims |
| Johnson & JohnsonXarelto | $103 | $23,65133 claims |
| Boehringer IngelheimJardiance | $50 | $17,31526 claims |
| Lilly USA, LLCMounjaro | $474 | $15,48816 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $84 | $11,66612 claims |
| MerckJanuvia | $115 | $9,57013 claims |
| BayerKerendia | $270 | $7,91312 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $62 | $3,349285 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $15 | $3,26013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in McMinnville
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
- Nathaniel FondellMedford$21K
- Carl EricksonMilwaukie$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.